ZUPREME-1 topline results report up to 10.7% mean weight loss with petrelintide

What happened

Roche reported topline findings from ZUPREME-1, a randomized phase 2 trial of petrelintide. Participants had BMI-defined obesity, or overweight accompanied by another condition tied to weight. Petrelintide is an investigational long-acting analog of amylin, a hormone involved in appetite and meal-related signaling.

The double-blind, placebo-controlled study enrolled 493 participants and compared five once-weekly injected dose regimens with placebo. The registered protocol describes a multinational, parallel-group dose-finding design. Treatment doses were increased at four-week intervals. Every arm included calorie reduction guidance and a physical activity increase.

According to the company announcement, all five active regimens produced statistically greater weight reduction than placebo at the 28-week primary endpoint. Weight continued to decline through week 42. Using an efficacy estimand, the best reported arm averaged 10.7% below baseline at that point. The placebo average was 1.7%. This difference met the company's stated significance test at p<0.001.

In the regimen the sponsor described as maximally effective, 4.8% of participants stopped treatment because of adverse events. The placebo figure was 4.9%. Roche said most digestive-system events were mild. For that active regimen, the company counted zero vomiting events and attributed no treatment withdrawals to gastrointestinal problems.

What it means

The trial offers dose-ranging evidence for a non-GLP-1 hormonal approach to weight management. The five regimens can help researchers select doses for later studies and explore whether amylin-based treatment can produce clinically useful weight reduction with acceptable tolerability.

The ClinicalTrials.gov record confirms the design and actual enrollment, while the company release supplies the outcome numbers. Reading both is important because a registry describes what investigators planned and a results announcement describes what the sponsor says occurred.

What it does not mean

Petrelintide is not an approved obesity medicine, and the announcement is not a prescribing recommendation. The 10.7% figure is the best reported group average under a specified analysis, not the result for every dose or a forecast for an individual.

The release does not provide a complete table of 42-week efficacy and safety results for all arms. Topline sponsor data have not yet received the scrutiny of a full peer-reviewed publication. A 493-person, 42-week trial also cannot establish uncommon risks, long-term outcomes, durability after treatment ends, or comparative effectiveness against an approved medication or bariatric surgery.